Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03861793
Recruitment Status : Recruiting
First Posted : March 4, 2019
Last Update Posted : August 25, 2020
Sponsor:
Information provided by (Responsible Party):
Alkermes, Inc.

Brief Summary:
This study will characterize the safety and tolerability and identify the recommended Phase 2 dose (RP2D) of subcutaneous (SC) ALKS 4230 as monotherapy and in combination with pembrolizumab.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumors Biological: ALKS 4230 Biological: Pembrolizumab Phase 1 Phase 2

Detailed Description:
This study will evaluate ALKS 4230 administered SC as lead-in monotherapy and in combination with pembrolizumab in subjects with advanced solid tumors.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 319 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-2 (001)
Actual Study Start Date : February 26, 2019
Estimated Primary Completion Date : June 2022
Estimated Study Completion Date : June 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: ALKS 4230
Administered via SC injection once every 7 days or once every 21 days at escalating doses
Biological: ALKS 4230
SC injection administered in the back of the arm or the abdomen

Experimental: ALKS 4230 + pembrolizumab
ALKS 4230 will be administered via SC injection once every 21 days at escalating doses or at the recommended phase 2 dose; pembrolizumab will be administered as an intravenous infusion given over 30 minutes; the dose level for pembrolizumab will be 200 mg per the approved label
Biological: ALKS 4230
SC injection administered in the back of the arm or the abdomen

Biological: Pembrolizumab
Administered as an intravenous (IV) infusion over 30 minutes
Other Name: Keytruda




Primary Outcome Measures :
  1. Incidence of Adverse Events (AEs), and identify the RP2D of ALKS 4230 in Part A [ Time Frame: From time of initiation of therapy until 30 days after last dose of study drug, assessed up to 24 months ]
    Includes AEs that are both serious and drug-related

  2. Number of subjects experiencing AEs that are both serious and drug-related in Part B [ Time Frame: From time of initiation of therapy until 30 days after last dose of study drug, assessed up to 24 months ]
    Includes AEs that are both serious and drug-related

  3. Clinical Activity of combination treatment with ALKS 4230 and pembrolizumab in each Part B tumor type. [ Time Frame: From time of therapy until the date of first documented tumor progression, assessed up to 24 months ]
    Overall Response rate (ORR) will be based on investigator review of radiographic and photographic images


Secondary Outcome Measures :
  1. Proportion of subjects with objective evidence of Complete Response (CR)/immune CR (iCR) [ Time Frame: From time of initiation of therapy until the date of first documented tumor progression, assessed up to 24 months ]
    Overall response rate (ORR) will be based on investigator review of radiographic or photographic images

  2. Proportion of subjects with objective evidence of Partial Response (PR)/immune PR (iPR) [ Time Frame: From time of initiation of therapy until the date of first documented tumor progression, assessed up to 24 months ]
    ORR will be based on investigator review of radiographic or photographic images

  3. Duration of response in subjects with CR/iCR [ Time Frame: Time from the first documentation of complete response, measured approximately every 6 weeks, to the first documentation of objective tumor progression or death due to any cause (estimated up to 24 months) ]
    CR/iCR duration

  4. Duration of response in subjects with PR/iPR [ Time Frame: Time from the first documentation of complete response, measured approximately every 6 weeks, to the first documentation of objective tumor progression or death due to any cause (estimated up to 24 months) ]
    PR/iPR duration

  5. Non-progression for Part B [ Time Frame: Assessed up to 24 months ]
    Time from first dose of SC ALKS 4230 to the time of progression or death

  6. Overall survival for Part B [ Time Frame: Assessed up to 24 months ]
    Time from first dose of SC ALKS 4230 to the time of death

  7. Serum concentrations of ALKS 4230 will be determined at various time points [ Time Frame: From time of initiation of therapy until the last treatment cycle (each cycle is 21 days), assessed up to 24 months ]
    Concentration vs time and standard pharmacokinetic (PK) parameters will be summarized by dose level

  8. Serum will be assayed for the presence of anti-ALKS 4230 antibodies [ Time Frame: From time of initiation of therapy until the last treatment cycle (each cycle is 21 days), assessed up to 24 months ]
    Results will be summarized by dose level

  9. Immunophenotyping of peripheral blood mononuclear cells will be performed by flow cytometry at various time points [ Time Frame: From time of initiation of therapy until the last treatment cycle (each cycle is 21 days), assessed up to 24 months ]
    Results will be summarized by dose level

  10. Serum concentrations of proinflammatory cytokines will be assessed using a multiplex method at various time points [ Time Frame: From time of initiation of therapy until the last treatment cycle (each cycle is 21 days), assessed up to 24 months ]
    Results will be summarized by dose level



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • For Part A the subject has histological or cytological evidence of a solid tumor. For Part B the subject must have 1 of the unspecified adult solid tumor types defined in the protocol
  • Record of programmed cell death ligand 1 protein expression status, or availability of fresh or archival tumor tissue for cellular characterization and PD-L1 status
  • Subjects must have adequate liver function
  • Subjects must have adequate kidney function
  • Subjects must be recovered from the effects of any prior chemotherapy, immunotherapy, other prior systemic anticancer therapy, radiotherapy or surgery
  • Subjects who have received radiation therapy must wait at least 4 weeks after their last radiation treatment before enrollment into the study
  • Females of childbearing potential must have a negative pregnancy test within 7 days of the start of treatment and on Day 1 before the first dose is administered
  • Subject will agree to follow contraceptive requirements defined in the protocol
  • Additional criteria may apply

Exclusion Criteria:

  • Subject is currently pregnant, planning to become pregnant, or breastfeeding
  • Subjects with an active infection or with a fever ≥ 38.5°C within 3 days of the first scheduled day of dosing for Cycle 1
  • Subjects with active or symptomatic central nervous system metastases are excluded. Subjects with central nervous system metastases are eligible for the study if the metastases have been treated by surgery and/or radiation therapy, the subject is off corticosteroids for at least 2 weeks, and the subject is neurologically stable
  • Subjects with known hypersensitivity to any components of ALKS 4230 or to pembrolizumab or any of its excipients
  • Subjects who require pharmacologic doses of steroids; replacement doses, topical, ophthalmologic, and inhalational steroids are permitted
  • Subjects who developed autoimmune disorders while on prior immunotherapy, including pneumonitis, nephritis, and/or neuropathy
  • Subjects with any other concurrent uncontrolled illness, including mental illness or substance abuse, which may interfere with the ability of the subjects to cooperate and participate in the study
  • The subject is known to be positive for human immunodeficiency virus (HIV), hepatitis B or C, or active tuberculosis, or has a known history of tuberculosis
  • Additional criteria may apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03861793


Contacts
Layout table for location contacts
Contact: Jennifer Skinner 303-704-6798 Jennifer.skinner@syneoshealth.com

Locations
Layout table for location information
United States, California
Alkermes Investigational Site Recruiting
Los Angeles, California, United States, 90025
United States, District of Columbia
Alkermes Investigational Site Recruiting
Washington, District of Columbia, United States, 20007
United States, Georgia
Alkermes Investigational Site Recruiting
Atlanta, Georgia, United States, 30322
United States, Michigan
Alkermes Investigational Site Recruiting
Detroit, Michigan, United States, 48201
United States, New York
Alkermes Investigational Site Recruiting
Buffalo, New York, United States, 14263
United States, North Carolina
Alkermes Investigational Site Recruiting
Huntersville, North Carolina, United States, 28078
United States, Ohio
Alkermes Investigational Site Recruiting
Cincinnati, Ohio, United States, 45229
United States, Pennsylvania
Alkermes Investigational Site Recruiting
Philadelphia, Pennsylvania, United States, 19111
United States, South Carolina
Alkermes Investigational Site Recruiting
Charleston, South Carolina, United States, 29425
United States, Texas
Alkermes Investigational Site Recruiting
Austin, Texas, United States, 78705
Alkermes Investigational Site Recruiting
Houston, Texas, United States, 77030
Sponsors and Collaborators
Alkermes, Inc.
Investigators
Layout table for investigator information
Study Director: Alkermes Medical Director Alkermes, Inc.
Layout table for additonal information
Responsible Party: Alkermes, Inc.
ClinicalTrials.gov Identifier: NCT03861793    
Other Study ID Numbers: ALKS 4230-001
First Posted: March 4, 2019    Key Record Dates
Last Update Posted: August 25, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: At this time, IPD sharing has not been defined and/or decided if it will be shared.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Alkermes, Inc.:
Alkermes
IL-2
Interleukin-2
Oncology
Immuno-oncology
Cytokine
ALKS 4230
Pembrolizumab
Keytruda
PD-L1
Solid tumors
Immunotherapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Pembrolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents